Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the acquisition of Ordinary Shares by specific executives on May 12, 2014, at a price of 1,612.8925 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Directors and senior managers acquired shares via the ShareReward Plan.
- Transaction Date: May 12, 2014.
- Share Price: 1,612.8925 pence per Ordinary Share.
- Volume: Each listed individual acquired 8 shares via personal contribution and 8 shares via company matching contribution.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.